BioSpace News Archive

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its novel AMZEEQTM (minocycline) topical foam, 4%.

CareCentrix, the leading provider of home-based, post-acute care solutions celebrates the success of its Women’s Network, an employee resource group aimed at promoting the advancement and inclusion of women leaders within CareCentrix

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 1, 2019 to discuss its third quarter operating results

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen’s Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia (ITP), a rare, serious autoimmune disease characterized by low platelet counts.

Noxopharm (ASX: NOX) announces that it will apply its glutamate-inhibition technology to the treatment of glioblastoma multiforme (GBM).

The Multiple Myeloma Research Foundation (MMRF) was honored to have General Colin L. Powell (Ret.) as the keynote speaker at the annual MMRF Chicago Awards Dinner fundraiser at the Four Seasons Chicago on October 17, 2019.

Moberg Pharma AB implements changes in the management team where Mark Beveridge, VP Finance, reassumes responsibility for the finance function and replaces Sarah Hellerfelt who has decided to leave her position as CFO for the company.

As a precautionary measure, Sanofi will conduct a voluntary recall of Zantac OTC in the U.S. and Canada.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), today announced that Eric A. Adams, President and Chief Executive Officer of InMed, will be presenting at the BIO Investor Forum in San Francisco:

The report, HDAC (histone deacetylase) inhibitors market 2019-2023, has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on RoA and geography for the forecast period 2019-2023.